In a report released today, James Jang from Univest Securities maintained a Buy rating on Alzamend Neuro (ALZN – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $1.07.
According to TipRanks, Jang is an analyst with an average return of -8.3% and a 34.87% success rate.
Currently, the analyst consensus on Alzamend Neuro is a Moderate Buy with an average price target of $15.00.
See the top stocks recommended by analysts >>
Based on Alzamend Neuro’s latest earnings release for the quarter ending April 30, the company reported a quarterly GAAP net loss of $3.87 million. In comparison, last year the company had a GAAP net loss of $1.26 million
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALZN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline of product candidates consist of two novel therapeutic drug candidates namely AL001 a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, and; AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s.
Read More on ALZN:
- Major shareholder announcement – Dimensional Holdings Inc.
- Nasdaq Launches Nasdaq Primary in Partnership with Onbrane
- BIT5IVE LLC and MGT Capital Announce Letter of Intent to Merge
- Conduent Technology and Expertise Plays Critical Role in Public Health Response to Monkeypox
- Hillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20